Oct. 29, 2009 (PR Newswire) --
HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
"Shire is committed to the advancement of ADHD treatment research and is leading the way in developing a diverse range of safe and effective ADHD treatments," said Michael Yasick, Senior Vice President of the Shire ADHD Business Unit. "We are excited to provide new scientific data on our ADHD portfolio, which includes the newest FDA-approved ADHD treatment INTUNIV; Vyvanse, the first prodrug stimulant for the treatment of ADHD; and Daytrana, the only patch approved for the treatment of ADHD. We are proud to provide important contributions to the growing body of research on our ADHD portfolio to the medical community."
Following is a summary of the key Shire scientific presentations. Information about these data presentations mentioned in this media alert is embargoed until the respective presentation sessions have taken place at the meeting.
INTUNIV (guanfacine) Extended Release Tablets
October 29, 2009; 6:30 pm to 9:00 pm ET / 12:30 pm to 3:00 pm HT
Effects of Guanfacine Extended Release in Children Aged 6 to 12 With Oppositional Symptoms and a Diagnosis of ADHD
Poster Presentation # 3.8
October 29, 2009; 6:30 pm to 9:00 pm ET / 12:30 pm to 3:00 pm HT
Twenty-Four-Month Effectiveness of Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With ADHD
Poster Presentation # 3.24
Vyvanse (lisdexamfetamine dimesylate) Capsules CII
October 29, 2009; 6:30 pm to 9:00 pm ET / 12:30 pm to 3:00 pm HT
The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age With ADHD in a Double-Blind, Placebo-Controlled Trial
Poster Presentation # 3.6
October 29, 2009; 6:30 pm to 9:00 pm ET / 12:30 pm to 3:00 pm HT
Reading Performance as a Function of Treatment With Lisdexamfetamine Dimesylate in Elementary School Children Diagnosed With ADHD
Poster Presentation # 3.19
October 29, 2009; 6:30 pm to 9:00 pm ET / 12:30 pm to 3:00 pm HT
Clinical Response and Symptomatic Remission in Children Treated With Lisdexamfetamine Dimesylate for ADHD
Poster Presentation # 3.20
October 29, 2009; 6:30 pm to 9:00 pm ET / 12:30 pm to 3:00 pm HT
Cardiovascular Outcomes in Children and Adults Treated With Lisdexamfetamine Dimesylate for ADHD
Poster Presentation # 3.23
Daytrana (methylphenidate transdermal system) CII
October 30, 2009; 3:00 pm to 5:30 pm ET / 9:00 am to 11:30 am HT
Pharmacokinetics of Methylphenidate Transdermal System and Osmotic-Release Oral System Methylphenidate in Children and Adolescents With ADHD
Poster Presentation # 4.52
October 30, 2009; 3:00 pm to 5:30 pm ET / 9:00 am to 11:30 am HT
Pharmacokinetic Predictors of Abuse-Related Liking With Transdermal and Subcutaneous Methylphenidate
Poster Presentation # 4.54
October 30, 2009; 3:00 pm to 5:30 pm ET / 9:00 am to 11:30 am HT
Evaluation of the Tolerability and Effectiveness of the Methylphenidate Transdermal System Over 6 Months in Adolescents With ADHD
Poster Presentation # 4.55
Additional information about INTUNIV and Full Prescribing Information are available at http://www.intuniv.com.
Additional information about Vyvanse and Full Prescribing Information, including the Medication Guide, are available at http://www.vyvanse.com.
Additional information about Daytrana and Full Prescribing Information, including the Medication Guide, are available at http://www.daytrana.com.
INTUNIV IMPORTANT SAFETY INFORMATION
INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17. Efficacy was established in two controlled clinical trials (8 and 9 weeks in duration). The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.
